Transdermal penetration of zalcitabine, lamivudine and synthesised N-acyl lamivudine esters

International Journal of Pharmaceutics

Volumn 351, Issue 1-2, 2008, Pages 186-193

  Gerber, Minja ^a   Breytenbach, Jaco C ^a   du Plessis, Jeanetta ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

Author keywords

Lamivudine; N acyl lamivudine esters; Skin penetration; Transdermal delivery; Zalcitabine

Indexed keywords

ESTER DERIVATIVE; LAMIVUDINE; N ACYL LAMIVUDINE ESTER; UNCLASSIFIED DRUG; ZALCITABINE;

ACYLATION; ANALYTIC METHOD; ARTICLE; CORRELATION ANALYSIS; DRUG DELIVERY SYSTEM; DRUG PENETRATION; EPIDERMIS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SOLUBILITY;

ADMINISTRATION, CUTANEOUS; EMULSIONS; ESTERS; FEMALE; HUMANS; LAMIVUDINE; MICROSCOPY, CONFOCAL; REVERSE TRANSCRIPTASE INHIBITORS; SKIN; SKIN ABSORPTION; SOLUBILITY; ZALCITABINE;

EID: 38749099096     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.09.040     Document Type: Article

References (28)

1. Abdou H.M. Dissolution Bioavailability and Bioequivalence (1989), Mack Publishing Company, Easton, Pennsylvania p. 554
2. Brinkman K., and Ter Hofstede H.J.M. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: lactic acidosis, risk factors and therapeutic options. AIDS Rev. 1 (1999) 140-146
3. De Clercq E. Antiviral drugs in current clinical use. J. Clin. Virol. 30 (2004) 115-133
4. Flexner C. Antiretroviral agents and treatment of HIV infection. In: Brunton L.L., Lazo J.S., and Parker K.L. (Eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. (2006), McGraw-Hill, New York 1273-1314
5. Flynn G.L., and Yalkowsky S.H. Correlation and prediction of mass transport across membranes I. Influence of alkyl chain length on flux determining properties of barrier and diffusant. J. Pharm. Sci. 61 (1972) 838-852
6. Gerber M., Breytenbach J.C., Hadgraft J., and Du Plessis J. Synthesis and transdermal properties of acetylsalicylic acid and selected esters. Int. J. Pharm. 310 (2006) 31-36
7. Goosen C., Laing T.J., Du Plessis J., Goosen T.C., Lu G., and Flynn G.L. Percutaneous delivery of thalidomide and its N-alkyl analogs. Pharm. Res. 19 (2002) 434-439
8. Gregg C.R. Drug interactions and anti-infective therapies. Am. J. Med. 106 (1999) 227-237
9. Grobler, A.F., 2004. Emzaloid™ Technology. Potchefstroom: North-West University. p. 20, (confidential: concept document).
10. Guy R.H., and Hadgraft J. Selection of drug candidates for transdermal drug delivery. In: Hadgraft J., and Guy R.H. (Eds). Transdermal Drug Delivery: Developmental Issues and Research Initiatives (1989), Marcel Dekker, New York 324
11. Hadgraft J. Recent developments in topical and transdermal delivery. Eur. J. Drug Metab. Pharmacokinet. 21 (1996) 165-173
12. Hadgraft J., and Lane M.E. Passive transdermal drug delivery systems: recent considerations and advances. Am. J. Drug Deliv. 4 (2006) 153-160
13. Hadgraft J., Du Plessis J., and Goosen C. The selection of non-steroidal anti-inflammatory agents for dermal delivery. Int. J. Pharm. 207 (2000) 31-37
14. Jack L., Cameron B.D., Scott R.C., and Hadgraft J. In vitro percutaneous absorption of salicylic acid: effect of vehicle pH. In: Scott R.C., Guy R.H., Hadgraft J., and Bodde H.E. (Eds). Prediction of Percutaneous Penetration (1991), IBC Technical, London 515-518
15. Junginger H.E., Hofland H.E.J., and Bowstra J.A. Liposomes and niosomes: interactions with human skin. Cosmet. Toilet. 106 (1991) 45-46
16. Kim D.D., and Chien Y.W. Transdermal delivery of zalcitabine: in vitro skin permeation study. Aids 9 (1995) 1331-1336
17. Kim D.D., and Chien Y.W. Simultaneous skin permeation of dideoxynucleoside-type anti-HIV drugs. J. Control. Release 40 (1996) 67-76
18. Kim D.D., and Chien Y.W. Transdermal delivery of dideoxynucleoside-type anti-HIV drugs 2. The effect of vehicle and enhancer on skin permeation. J. Pharm. Sci. 85 (1996) 214-219
19. Kligman A.M., and Christophers E. Preparation of isolated sheets of human stratum corneum. Arch. Dermatol. 88 (1963) 702-705
20. Merigan T.C., Skowron G., Bozzette S.A., Richman D., Uttamchandani R., Fischl M., Sxhooley R., Hirsch M., Soo W., and Pettinelli C. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study. Ann. Intern. Med. 110 (1989) 189-194
21. Monene L.M., Goosen C., Breytenbach J.C., Hadgraft J., and du Plessis J. Percutaneous absorption of cyclizine and its alkyl analogues. Eur. J. Pharm. Sci. 24 (2005) 239-244
22. Roberts W.J., and Sloan K.B. Prediction of transdermal flux of prodrugs of 5-fluorouracil, theophylline, and 6-mercaptopurine with a series/parallel model. J. Pharm. Sci. 89 (2000) 1415-1431
23. Saunders J.C.J., Davis H.J., Coetzee L., Botha S., Kruger A.E., and Grobler A. A novel skin penetration enhancer: elevation by membrane diffusion and confocal microscopy. J. Pharm. Pharm. Sci. 2 (1999) 99-107
24. Schiffman S.S., Zervakis J., Shaio E., and Heald A.E. Effect of nucleoside analogs zidovudine, didanosine, stavudine, and lamivudine on the sence of taste. Nutrition 15 (1999) 854-859
25. Smith K.L. Penetrant characteristics influencing skin absorption. In: Kemppainen B.W., and Reifenrath W.G. (Eds). Methods for Skin Absorption (1990), CRC Press, Boca Raton 219
26. In: Sweetman S.C. (Ed). Martindale: The complete drug reference. 33rd ed. (2002), The Pharmaceutical Press, London 635-636
27. Touitou E., Junginger H.E., Weiner N.D., Nagai T., and Mezei M. Liposomes as carriers for topical and transdermal delivery. J. Pharm. Sci. 83 (1994) 1189-1203
28. UNAIDS, 2006. Report on global AIDS epidemic 2006. http://www.unaids.org/en/HIV_data/2006GlobalReport/default.asp. (date of access: November 10, 2006).